Study summary · research use only
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review examines the pharmacological profile, clinical trial findings, and adverse-effect data of survodutide, an investigational dual agonist targeting the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), drawing on human phase 1 and 2 clinical trial data in metabolic dysfunction-associated steatohepatitis (MASH). The authors describe survodutide's dual agonism as showing potential in resolving MASH and promoting fibrosis regression, exceeding that reported for selective GLP-1R agonists in the trials reviewed. Gastrointestinal adverse effects were reported as generally manageable. The review notes that survodutide is progressing into phase 3 clinical development for MASH and related comorbidities.
Abstract
Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic dysfunction-associated steatohepatitis (MASH) through their glucose-lowering and weight-reducing properties, their efficacy in promoting fibrosis regression remains unproven. Survodutide, an investigational dual agonist that simultaneously targets both the glucagon receptor (GCGR) and GLP-1 R, has emerged as a promising therapeutic candidate for the comprehensive management of obesity and MASH. By engaging these two critical receptors, this drug has the potential to offer a broad spectrum of metabolic benefits, addressing multiple pathogenic mechanisms underlying these interrelated disorders. This review examines the pharmacological profile, clinical efficacy, and safety data of survodutide derived from phase 1 and 2 clinical trials. Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression. The drug is generally well tolerated, with primarily manageable gastrointestinal adverse effects. As survodutide progresses through phase 3 clinical development, its potential to provide a more effective and holistic approach to treating MASH and its comorbidities may significantly improve patient outcomes and quality of life.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.